A phase II, open-label, multi-center study to evaluate safety and immunogenicity of a booster dose of H5N1 (surface antigen adjuvanted with MF59C.1) influenza vaccine in non-elderly adult and elderly subjects.

Trial Profile

A phase II, open-label, multi-center study to evaluate safety and immunogenicity of a booster dose of H5N1 (surface antigen adjuvanted with MF59C.1) influenza vaccine in non-elderly adult and elderly subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (47) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top